Anthropic Acquires One-Person Biotech Company Mithril Medicine, Launches In-House Drug Development Program

TechFlow reported on October 28 that, according to TNW, Anthropic announced in a Tuesday blog post that it had acquired Mithril Medicine. The company has only one employee and is developing therapies for two rare forms of muscular dystrophy. The terms of the deal were not disclosed, and founder Cody Tranbarger has joined Anthropic. According to Anthropic, Mithril used Claude to manage contracts, logistics, and experiments with 11 external laboratories, advancing candidate therapies from concept to positive results in mouse experiments in less than 18 months. According to its technical report, which has not yet been peer-reviewed, mice treated with one antibody-design therapy had approximately twice the grip strength of untreated mice. If the candidate drug performs consistently, it could enter human clinical trials as early as late 2028.

Source: TechFlow